<?xml version="1.0" encoding="UTF-8"?>
<p id="Par107">Progression-free survival will be measured as time to either progression or death, whichever occurs first. Efficacy Evaluation will be performed at baseline, at 6 months, at 1 year, then subsequently every year until the end of study, using the same imaging method as for baseline (CT scan or MRI or PET if indicated).</p>
